- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
TCR-like antibodies in cancer immunotherapy ; volume:12 ; number:1 ; day:14 ; month:9 ; year:2019 ; pages:1-13 ; date:12.2019
Journal of hematology & oncology ; 12, Heft 1 (14.9.2019), 1-13, 12.2019
- Urheber
-
He, Qinghua
Liu, Zhaoyu
Liu, Zhihua
Lai, Yuxiong
Zhou, Xinke
Weng, Jinsheng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-019-0788-4
- URN
-
urn:nbn:de:101:1-2020021323151481362526
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- He, Qinghua
- Liu, Zhaoyu
- Liu, Zhihua
- Lai, Yuxiong
- Zhou, Xinke
- Weng, Jinsheng
- SpringerLink (Online service)
Ähnliche Objekte (12)
TCR diversity – a universal cancer immunotherapy biomarker?
Application of Nano-Antibodies for Cancer Immunotherapy
Next-Generation TCR-transgenic T cells for Immunotherapy
TCR engineered T cells for solid tumor immunotherapy
From antibodies to living drugs: Quo vadis cancer immunotherapy?
Bispecific antibodies come to the aid of cancer immunotherapy
Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
Elucidating the potential of IgA antibodies for cancer immunotherapy
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Application of Nano-Antibodies for Cancer Immunotherapy
Next-Generation TCR-transgenic T cells for Immunotherapy
TCR engineered T cells for solid tumor immunotherapy
From antibodies to living drugs: Quo vadis cancer immunotherapy?
Bispecific antibodies come to the aid of cancer immunotherapy
Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
Elucidating the potential of IgA antibodies for cancer immunotherapy
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
TCR diversity – a universal cancer immunotherapy biomarker?
Application of Nano-Antibodies for Cancer Immunotherapy
Next-Generation TCR-transgenic T cells for Immunotherapy
TCR engineered T cells for solid tumor immunotherapy
From antibodies to living drugs: Quo vadis cancer immunotherapy?
Bispecific antibodies come to the aid of cancer immunotherapy
Validation and promise of a TCR mimic antibody for cancer immunotherapy of hepatocellular carcinoma
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Merge Two into One: Multispecific Symmetric Antibodies for Cancer Immunotherapy
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
Elucidating the potential of IgA antibodies for cancer immunotherapy